The adobe flash plugin is needed to view this content. Exploring the role of incretinbased therapy in type 2 diabetes. Inhibition of the degrading enzyme dpp4 is an alternative incretin based approach to type 2 diabetes therapy 42. Use of incretin therapy in the treatment of type 2 diabetes.
In patients with type 2 diabetes shown on the right, the same effect was observed but was diminished in magnitude. Early initiation of combination therapy has been proposed as an approach to achieve glycemic goals earlier and delay the deterioration of glycemic control and with possible better preservation of. Treatment with glp1 receptor agonists incretin mimetics and dpp4 inhibitors incretin. Incretin based therapies and their role in the management of type 2 diabetes. Incretin system in the pathogenesis of type 2 diabetes and the. P3298 were among the first to show the potential of such inhibitor therapy 45. Type 2 diabetes is a progressive disorder characterized by increasing hyperglycemia and the need to gradually intensify therapy in order to achieve and maintain glycemic control.
We aimed to systematically assess the cardiovascular effects of incretinbased therapies in patients with type 2 diabetes. The diminished incretin effect observed in patients with type 2 diabetes may be due to reduced responsiveness of pancreatic beta cells to glp1 and gip or to impaired secretion of the relevant incretin hormone. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Nevertheless, the clinical effects are in great diversity for poorly controlled type 2 diabetes patients. Incretins therapy for type 2 diabetes mellitus dr majeed mustafa. Incretins therapy for type 2 diabetes mellitus dr majeed mustafa, frcp ed consultant endocrinologi 1 incretins therapy for type 2 diabetes mellitus dr. Therapy of type 2 diabetes mellitus, update, part 2. Incretinbased therapies for patients with type 1 diabetes. Background to assess the cardiovascular cv risk associated with the use of incretin based therapy in adult patients with type 2 diabetes mellitus t2dm primary prevention group with low cv risks. It has a structural homology of 53% with glp1 and has a lasting effect of maximum 7 hours. The incretin defect in type 2 diabetes incretin defect insulin resistance relative insulin deficiency hyperglycemia type 2 diabetes incretin effect accounts for up to 70% of the insulin response to oral glucose intake1 1. Metformin, mg bid glimepiride, 4 mgday the hba1c in clinic is 9. As longitudinal studies of type 2 diabetes provide evidence. The unique role of incretinbased therapy in type 2 diabetes.
Introduction type 2 diabetes is sometimes called a life style disease as it more common in people who dont do enough exercise, have an unhealthy diet and obese. Diabetes afflicts an estimated 217 million people worldwide, and the world health organization has predicted that this number will potentially rise to a minimum of 366 million by 2030, of whom the majority have type 2 diabetes. Careful postmarketing surveillance for adverse effects, especially among the dpp4 inhibitors, and continued evaluation in longerterm. Incretin based drugs, such as glucagonlike peptide1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus.
Thus, a new therapeutic window that uses glp1 as a way of increasing insulin secretion has been identified. Medications based on incretins are used in the treatment of diabetes mellitus type 2. Effective weight loss, lack of significant hypoglycaemia, and favourable cardiometabolic profile make incretin based therapies an attractive treatment option for type. Incretin physiology and its role in type 2 diabetes mellitus the. Glp1 ras can provide robust glucosecontrol capability in type 2 diabetes 12. Ralph defronzo, md, chief of the diabetes division at the university of texas health science center in san antonio, explains the moa of each of the incretin hormones, gip and glp1. Comparison of efficacy between incretinbased therapies for. The role of incretinbased therapies in the management of. Concerns about the cardiovascular safety of incretinbased therapies, which include dipeptidyl peptidase4 inhibitors and glucagonlike peptide1 receptor agonists, in patients with type 2 diabetes have been raised. Incretin peptides, principally glp1 and gip, regulate islet hormone secretion, glucose concentrations, lipid metabolism, gut motility, appetite and body weight, and immune function, providing a scientific basis for utilizing incretin based therapies in the treatment of type 2 diabetes. The efficacy of incretin therapy in patients with type 2. Loss of the incretin effect is an early characteristic of type 2 diabetes, and exploitation of glp1 physiology has led to the development of two novel drug classes glp1 analogues and. Studies suggest that one reason bariatric surgery may help people with diabetes is that, in addition to causing weight loss, it seems to stimulate incretin production. Incretinbased therapies for the treatment of type 2 diabetes.
In this study, we examined the efficacy of incretin therapy in patients with insulintreated type 2 diabetes undergoing hemodialysis. Based on the 2014 national diabetes statistics report, 29. It has been accredited by the american association of diabetes educators aade for nurses, dietitians, and pharmacists. Glp1based therapies for treatment of type 2 diabetes. The importance of incretin therapies for managing type 2. The authors investigated whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2. Incretins and sglt2 inhibitors in the treatment of diabetes.
Many of the available treatment options have side effects such as weight gain which often affect patients willingness to continue the treatment. Consultant endocrinologist diabetologist gdc hospital, november 15th 2008 2 the incretin effect ogtt and matched iv infusion nauck et al. A quarter of a century after the discovery of incretin hormones and their impaired regulation of insulin and glucagon secretion in type 2 diabetes,1 specific treatments to improve the diminished incretin effect have become widely available for glycaemic control in type 2 diabetes. Therapy of type 2 diabetes mellitus, update, part 3. Case 1 a 58 year old man comes to the clinic for a diabetes visit. Aug 23, 2010 incretin based therapy of type 2 diabetes mellitus by prof. Incretin based therapy of type 2 diabetes mellitus is the property of its rightful owner. Methods the clinical studies on incretin based therapy published in medical journals until august 2014 were comprehensively searched using medline, embase and central with no language restriction. Incretin based therapy of type 2 diabetes mellitus 1. Medications based on incretins are used in the treatment of diabetes mellitus type 2 several longlasting glp1 analogs having insulinotropic activity have been developed, and several, including dulaglutide trulicity, exenatide byetta, liraglutide victoza, semaglutide ozempic and rebylsus and exenatide extendedrelease bydureon, have been approved for use in the u. Safety and efficacy of incretinbased therapies in patients with.
Eligible studies included randomized controlled trials evaluating incretin based therapy in adults with type 2 diabetes and estimated glomerular filtration rates 2. Physical activity considerations for choice of glp1 receptor agonist efficacy of glp1 receptor agonists vs. Based therapy in type 2 diabetes is supported by an educational grant from novo nordisk inc. Use of incretin therapy in the treatment of type 2. Incretinbased therapies address the progressive nature of type 2 diabetes mellitus, not only by. Nov 30, 2012 type 2 diabetes mellitus is widely prevalent and is often coexistent with obesity. We have the rapidacting glinides, which are shortacting insulin secretagogues that lower postmeal glucose levels. Exploring the role of incretinbased therapy in type 2. The authors investigated whether the reduced incretin effect observed in patients with type 2 diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the diabetic state. A1c type 2 diabetes, the blood sugar may be too high after a meal, even if you eat very little carbohydrate cho. The glucoselowering actions of gip the secretion of normal or increased glp1 reduced gip glp1 much weaker or absent resistance preserved in type 2 diabetes the incretin hormones and pathophysiology of type 2 dm 112 nauck ma, et al.
Incretins are a group of metabolic hormones that stimulate a decrease in blood glucose levels. Incretinbased therapies address the progressive nature of type 2 diabetes. Pathophysiology of type 2 diabetes the glucagon factor in contrast, the glucagon secretion in type 2 diabetics is not decreased, and may even. The two most recently approved classes of therapeutic agents for the treatment of type 2 diabetes, glucagonlike peptide1 glp1 receptor glp1r agonists and dipeptidyl peptidase4 inhibitors dpp4i, exert their actions through potentiation of incretin receptor signaling. Incretinbased therapy new treatment oppyptions for type 2 diabetes.
Incretin based therapy new treatment oppyptions for type 2 diabetes. Aug 15, 2012 ralph defronzo, md, chief of the diabetes division at the university of texas health science center in san antonio, explains the moa of each of the incretin hormones, gip and glp1, and how the. In the three amigo studies, a total of 1,441 type 2 diabetic patients were included, and. Incretin based therapy of type 2 diabetes mellitus 1 slideshare. The two most important incretin hormones are called glucagonlike peptide1 glp1 and glucosedependent insulinotropic polypeptide gip.
Safety and efficacy of incretinbased therapies in patients. Selecting therapy in type 2 diabetes, cont on the next slide, we have the remainder of the agents. Recent clinical trials indicate that incretinbased therapies dipeptidyl. Several longlasting glp1 analogs having insulinotropic. Pdf incretinbased therapy of type 2 diabetes mellitus. Activation of glp1 and gip receptors also leads to nonglycemic effects in multiple tissues, through direct.
Pdf incretinbased therapies for type 2 diabetes mellitus. Interventions incretin based therapies dipeptidyl peptidase 4 inhibitors and glucagonlike peptide 1 receptor agonists compared to placebo or active. This program has been accredited by the american association of diabetes educators aade for nurses, dietitians, pharmacists, and pharmacy technicians. Incretin treatments consist of either oral dpp4 inhibitors, which decrease the clearance of secreted incretins. Efficacy of incretin based therapy exenatide, the first incretin mimetic developed was incorporated into medical practice in 2005 and has been used in the therapy of type 2 diabetes mellitus in romania since 2008.
Type 2 diabetes was previously seen mainly in older adults, however it is becoming more common in young children due to obesity and overweight children. Management of type 2 diabetes normally involves lifestyle modification diet, exercise plus treatment with antidiabetic drugs, including members of the. Ppt incretins therapy for type 2 diabetes mellitus dr. When you have type 2 diabetes, the blood sugar may be too high after a meal, even if you eat very little carbohydrate cho. Jan 01, 2014 incretin based therapy is associated with improved glycemic control by boosting glp1 levels. Pharmacology, physiology, and mechanisms of incretin hormone. All patients were hospitalized and switched from insulin therapy to incretin therapy. Although incretin therapy is clinically available in patients with type 2 diabetes undergoing hemodialysis, no study has yet examined whether incretin therapy is capable of maintaining glycemic control in this group of patients when switched from insulin therapy. The physiological response to oral ingestion of nutrients, involving the incretin system, is reduced in some patients with type 2 diabetes but may be augmented by administration of glp1 receptor. Efficacy and safety of incretin therapy in type 2 diabetes. This study is designed to understand the pharmacological effects and genetic variation of incretin based therapy on type 2 diabetes. After patients were admitted to hospital, blood glucose was controlled by insulin therapy targeting a fasting blood glucose level of ppt presentation. The american diabetes association ada and the european association for the study of diabetes easd have proposed a set of patient and disease characteristics that have utility in guiding a patientcentered approach for the management of type 2 diabetes. Incretin based therapypy pp y is supported by an educational grant from novo nordisk inc.
Incretinbased drugs, such as glucagonlike peptide1 receptor agonists and dipeptidyl peptidase 4 inhibitors, are now routinely used to treat type 2 diabetes mellitus. Ppt incretin based therapy of type 2 diabetes mellitus. Incretinbased therapies dipeptidyl peptidase 4 inhibitors and glucagonlike peptide 1 receptor. The incidence and prevalence of type 2 diabetes are rising steadily, fuelled in part by a concomitant increase in the worldwide rates of obesity. The incretin system has become an important target in the treatment of type 2 diabetes in recent years, and glucagonlike peptide 1 glp1 is of particular interest for its glucoselowering effects.
After patients were admitted to hospital, blood glucose was controlled by insulin therapy targeting a fasting blood glucose level of incretin hormones and their impaired regulation of insulin and glucagon secretion in type 2 diabetes,1 specific treatments to improve the diminished incretin effect have become widely available for glycaemic control in type 2 diabetes. With regard to incretinrelated therapies, some patients with type 2 diabetes. If so, share your ppt presentation slides online with. Download figure open in new tab download powerpoint. Clinical overview epidemiology of diabetes ageadjusted percentage of us adults with diagnosed diabetes ageadjusted percentage of us adults with obesity complications of diabetes recommendations. Incretin hormone is a hormone that stimulates insulin secretion in response to meals. After patients were admitted to hospital, blood glucose was controlled by insulin therapy targeting a fasting blood glucose level of majeed mustafa, frcp ed consultant endocrinologi 1 incretins therapy for type 2 diabetes mellitus dr. Understanding how these hormones work is helping to yield new treatments for type 1 and type 2 diabetes. Clinical application of incretinbased therapy american journal of. Incretinbased therapies for type 2 diabetes sciencedirect. Incretin based treatments diabetes education online. Jul 11, 2007 conclusions incretin therapy offers an alternative option to currently available hypoglycemic agents for nonpregnant adults with type 2 diabetes, with modest efficacy and a favorable weightchange profile. Incretin based therapy for poorly controlled type 2 diabetic.
Incretin based therapy of type 2 diabetes mellitus if betacell function is normal, one can compensate. T1 use of incretin therapy in the treatment of type 2 diabetes mellitus. Incretin based therapy of type 2 diabetes mellitus by prof. Incretinbased therapies for the treatment of type 2. Medicines, called incretin based treatments, are now available to control postmeal glucagon, and help reduce the post meal blood sugars.
Incretin based therapies, either incretin enhancers eg, dipeptidyl peptidase4 dpp4 inhibitors such as gliptins or incretin mimetics eg, glucagonlike peptide1 glp1 receptor agonists are increasingly used for treatment of type 2 diabetes mellitus, because of their good glucoselowering activity without induction of hypoglycaemia or weight gain. Pro et contra of incretin therapy in type 2 diabetes. Type 2 diabetes is a complex metabolic disorder characterized by hyperglycemia arising from a combination of insufficient insulin secretion together with resistance to insulin action. Incretinbased therapypy pp y is supported by an educational grant from novo nordisk inc. The alphacell as target for type 2 diabetes therapy. Incretin hormone therapy benefits newly diagnosed type 2. Research has shown that people with type 2 diabetes dont have enough incretins, which could exacerbate the problem of high blood glucose. Therapy of type 2 diabetes mellitus, update, part 1. Clinical overview powerpoint presentation free to download id. Glucagonlike peptide 1 receptor agonists for type 2 diabetes. Mar 12, 20 incretin hormone is a hormone that stimulates insulin secretion in response to meals.
1228 1379 1450 1294 1485 841 399 1014 1135 694 269 1229 1411 598 567 638 1062 573 216 41 1402 272 6 673 120 482 439 1234 361 1331 766 688 42 646 385